Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2007, the company has established itself as a leader in developing innovative injectable products, particularly in the areas of oncology and critical care. With a focus on improving patient outcomes, Eagle Pharmaceuticals offers unique formulations that enhance the delivery and efficacy of established therapies. The company has achieved significant milestones, including the successful launch of its flagship product, Ryanodex, which is designed for the treatment of malignant hyperthermia. Eagle's commitment to quality and innovation has positioned it favourably in a competitive market, earning recognition for its contributions to patient care and drug accessibility. With operations extending across major regions in the US, Eagle Pharmaceuticals continues to drive advancements in the biopharmaceutical landscape.
DitchCarbon Score
How does Eagle Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eagle Pharmaceuticals, Inc.'s score of 13 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eagle Pharmaceuticals, Inc.'s reported carbon emissions
Eagle Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the pharmaceutical industry is increasingly focusing on reducing carbon footprints and enhancing sustainability practices. Eagle Pharmaceuticals may be expected to align with industry standards and pursue climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eagle Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
